Rebollo, Pablo http://orcid.org/0000-0002-7517-6540
García-López, Sofía
Povedano, Mónica
Cattinari, María G.
Martínez-Moreno, Mercedes
Terrancle, Ángeles
Cabello-Moruno, Rosana
Vázquez-Costa, Juan F. http://orcid.org/0000-0002-3043-7938
Funding for this research was provided by:
Roche España
Article History
Received: 23 October 2023
Accepted: 22 November 2023
First Online: 5 January 2024
Declarations
:
: Dr Vázquez-Costa is funded by grants from CUIDAME (Grant/Award Number: PIC188-18), the Instituto de Salud Carlos III (JR19/00030) and Generalitat Valenciana (Grant/Award Number: EMERGENTES/2021/055) and received personal fees from Biogen and Roche outside the submitted work. Dr. Mónica Povedano received personal fees from Biogen, Ferrer, Grifols, Italfarmaco and Roche outside the submitted work. Sofía García, Rosana Cabello and Ángeles Terrancle are employees of Roche Farma Spain. Pablo Rebollo is an employee of IQVIA Spain. Dr Mercedes Martínez has received payment for presentations, training courses and advisory boards from Biogen, Roche and Novartis. Dra. María Grazia Cattinari declares having attended medical congresses funded by Roche.
: SMA-Life study is conducted in accordance with the Good Clinical Practice Guidelines of the International Conference on Harmonisation and with the ethical principles of the Declaration of Helsinki. The study was approved by the institutional review board of the Hospital Universitari de Bellvitge (Barcelona, Spain; reference code: PR264/20). Written informed consent is obtained from all subjects.